keyword
MENU ▼
Read by QxMD icon Read
search

non radiographic axial spondyloarthritis

keyword
https://www.readbyqxmd.com/read/27887637/clinical-improvement-and-reduction-in-serum-calprotectin-levels-after-an-intensive-exercise-programme-for-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis
#1
Andrea Levitova, Hana Hulejova, Maja Spiritovic, Karel Pavelka, Ladislav Senolt, Marketa Husakova
BACKGROUND: The efficacy of exercise therapy for ankylosing spondylitis (AS) is well-documented, but dearth of information is for non-radiographic axial spondyloarthritis (nr-axSpA). Biomarkers like serum calprotectin, interleukins IL-6, IL-17 and tumour necrosis factor (TNF)-α may reflect the disease activity of axial spondyloarthritis (axSpA). In this study, we investigated clinical and laboratory parameters of both axSpA subgroups in response to intensive physical exercise. METHODS: Altogether, 46 patients with axSpA, characterised according to the Assessment of SpondyloArthritis International Society criteria as having nr-axSpA or AS underwent 6-month exercise programme...
November 25, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27863065/efficacy-and-safety-of-etanercept-in-patients-from-latin-america-central-europe-and-asia-with-early-non-radiographic-axial-spondyloarthritis
#2
James Cheng-Chung Wei, Wen-Chan Tsai, Gustavo Citera, Sameer Kotak, Lyndon Llamado
AIM: To evaluate etanercept in patients from Latin America, Central/Eastern Europe, and Asia with non-radiographic axial spondyloarthritis (nr-axSpA). METHODS: A subset analysis was performed on nr-axSpA patients from Argentina, Colombia, the Czech Republic, Hungary, Russia and Taiwan who were enrolled in EMBARK (NCT01258738). Patients received either etanercept 50 mg or placebo once weekly. The primary endpoint was proportion of patients achieving 40% improvement from baseline based on Assessment of SpondyloArthritis International Society (ASAS) criteria...
November 11, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/27856659/new-treatment-targets-for-axial-spondyloarthritis
#3
REVIEW
Joachim Sieper
Axial spondyloarthritis (axSpA) patients can be divided into those with structural damage in the SI joint visible on X-rays, termed radiographic axSpA or AS, and those in an earlier phase of the disease, without structural damage in the SI joint, termed non-radiographic axSpA. TNF-blockers have been shown to be highly effective in the treatment of active axSpA. Interestingly, conventional DMARDs and also non-TNF-blocker biologics targeting IL-1, IL-6 and T cells (abatacept) are not effective. Recent interest has focused on the cytokines IL-23 and IL-17 as potential treatment targets in axSpA...
December 2016: Rheumatology
https://www.readbyqxmd.com/read/27855973/systematic-review-of-clinical-humanistic-and-economic-outcome-comparisons-between-radiographic-and-non-radiographic-axial-spondyloarthritis
#4
Joachim Sieper, Xiaohan Hu, Christopher M Black, Kim Grootscholten, Remon W M van den Broek, Sumesh Kachroo
OBJECTIVE: To evaluate similarities and differences between non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) with regard to treatment effects and clinical, humanistic, and economic burdens. METHODS: In this systematic literature review, ACR 2015, EULAR 2015, EMBASE, and PubMed were searched for studies published between January 2010 and September 2015 that compared predefined clinical, humanistic, and economic aspects in nr-axSpA and AS...
September 13, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27817204/golimumab-for-the-treatment-of-axial-spondyloarthritis
#5
Carlo Palazzi, Salvatore D'angelo, Michele Gilio, Pietro Leccese, Angela Padula, Ignazio Olivieri
Anti-TNF drugs have represented an epochal revolution in the treatment of rheumatoid arthritis and spondyloarthritis. In the field of axial spondyloarthritis, golimumab, a fully human monoclonal anti-TNFα administered subcutaneously every 4 weeks, has shown significant efficacy and good safety in patients with ankylosing spondylitis. More recently, it was also indicated as an effective treatment for patients suffering from non-radiographic axial spondyloarthitits. Areas covered: A systematic literature search was completed, using the largest electronic databases (Medline, Embase and Cochrane), with the aim to review all data concerning the administration of golimumab in patients suffering from axial spondyloartritis...
November 9, 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27796520/prevalence-and-factors-associated-with-disturbed-sleep-in-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-systematic-review
#6
REVIEW
Shaaron Leverment, Emily Clarke, Alison Wadeley, Raj Sengupta
This review explores the prevalence and factors associated with disturbed sleep for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in order to clarify consistent findings in this otherwise disparate research field. The association of physical, demographic and psychological factors correlating with poor sleep was explored, and the effectiveness of interventions assessed. Ten electronic databases were searched: AMED, CINAHL, Embase, Medline, PsycINFO, PubMed, Scopus, Web of Science, OpenGrey and BASE...
October 28, 2016: Rheumatology International
https://www.readbyqxmd.com/read/27749215/burden-of-illness-associated-with-non-radiographic-axial-spondyloarthritis-a-multiperspective-european-cross-sectional-observational-study
#7
Joachim Sieper, Tim Holbrook, Christopher M Black, Robert Wood, Xiaohan Hu, Sumesh Kachroo
OBJECTIVES: To assess the impact of non-radiographic axial spondyloarthritis (nr-axSpA) on patients and society based on real-world evidence from the Adelphi nr-axSpA Disease Specific Programme, a cross-sectional survey of rheumatologists and their patients in Germany, France, Spain, Italy and the UK. METHODS: Physicians completed patient record forms for the next two patients consulting with nr-axSpA (diagnosis at the physician's judgement); patients were invited to complete a patient self-completion form...
August 31, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27600931/no-diagnostic-utility-of-antibody-patterns-against-klebsiella-pneumoniae-capsular-serotypes-in-patients-with-axial-spondyloarthritis-vs-patients-with-non-specific-low-back-pain-a-cross-sectional-study
#8
L T Hermansen, A G Loft, A A Christiansen, H L Munk, L Gilbert, A G Jurik, B Arnbak, C Manniche, U Weber, M Østergaard, S J Pedersen, T Barington, P Junker, K Hørslev-Petersen, O Hendricks
OBJECTIVES: To investigate whether antibody response patterns against Klebsiella pneumoniae capsular serotypes can discriminate patients with axial spondyloarthritis (axSpA) from patients with non-specific low back pain (LBP). METHOD: Immunoglobulin (Ig)G and IgA antibodies against K. pneumoniae capsular serotypes K2, K26, K36, and K50 were measured, and antibody seropositivity compared between groups and analysed for patient correlation in five different groups: (a) 96 patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA; (b) 38 patients with either a positive magnetic resonance imaging (MRI) scan as defined by ASAS or a positive human leucocyte antigen (HLA)-B27 status plus one clinical SpA feature, characterized as 'non-axSpA'; (c) 82 non-specific LBP patients; (d) 40 healthy blood donors and (e) 43 patients with diagnosed ankylosing spondylitis (AS) served as the negative and positive control groups...
September 7, 2016: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/27586785/prevalence-of-peripheral-and-extra-articular-disease-in-ankylosing-spondylitis-versus-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#9
Janneke J de Winter, Leonieke J van Mens, Désirée van der Heijde, Robert Landewé, Dominique L Baeten
BACKGROUND: Peripheral disease (arthritis, enthesitis and dactylitis) and extra-articular disease (uveitis, psoriasis and inflammatory bowel disease) is common in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). So far, however, summary data on the prevalence are lacking. The objective of this meta-analysis was to assess the prevalence of peripheral and extra-articular manifestations in ankylosing spondylitis (AS) and nr-axSpA. METHODS: We performed a systematic literature search to identify publications describing the prevalence of peripheral and extra-articular disease manifestations in patients with AS and nr-axSpA...
September 1, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27455991/etanercept-sb4-a-review-in-autoimmune-inflammatory-diseases
#10
Celeste B Burness, Sean T Duggan
Etanercept (SB4) [Benepali(®)], a tumour necrosis factor inhibitor that is a biosimilar of reference etanercept (Enbrel(®)), is approved in the EU for use in all adult indications for which reference etanercept is approved, namely rheumatoid arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis), psoriatic arthritis, and plaque psoriasis. The approval of etanercept (SB4) was based on the results of stringent comparability exercises designed to demonstrate similarity to reference etanercept in terms of quality, biological activity, efficacy, safety, and immunogenicity...
August 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27445459/golimumab-in-radiographic-and-nonradiographic-axial-spondyloarthritis-a-review-of-clinical-trials
#11
REVIEW
Eric Toussirot, Charline Vauchy, Delphine Binda, Fabrice Michel
Axial spondyloarthritis (Ax SpA) refers to chronic inflammatory rheumatic diseases that mainly affect the axial skeleton, leading to erosions and new bone formation in the sacroiliac joints and/or the spine. Ax SpA includes the radiographic form of the disease, ie, ankylosing spondylitis (AS), and the nonradiographic Ax SpA (non-Rx Ax SpA) forms. Anti-tumor necrosis factor alpha (TNFα) agents are used in the treatment of Ax SpA in patients who do not respond to or are intolerant to nonsteroidal anti-inflammatory drugs...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27411482/partial-remission-in-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-in-treatment-with-infliximab-plus-naproxen-or-naproxen-alone-associations-between-partial-remission-and-baseline-disease-characteristics
#12
Joachim Sieper, Martin Rudwaleit, Jan Lenaerts, Jürgen Wollenhaupt, Leysan Myasoutova, Sung-Hwan Park, Yeong W Song, Ruji Yao, Susan Huyck, Marinella Govoni, Denesh Chitkara, Nathan Vastesaeger
OBJECTIVES: To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission. METHODS: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial was a double-blind, randomised controlled trial of IFX in biologic-naïve patients with early, active axial SpA. Patients were randomised (2:1) to receive 28 weeks of treatment with i...
November 2016: Rheumatology
https://www.readbyqxmd.com/read/27385374/efficacy-safety-and-cost-per-responder-of-biologics-in-the-treatment-of-non-radiographic-axial-spondyloarthritis
#13
Ignazio Olivieri, Caterina Fanizza, Michele Gilio, Roberto Ravasio
Anti-tumour necrosis factor (TNF) agents are recommended as second-line therapy for patients with axial spondyloarthropathies. This analysis reviewed data on studies investigating the efficacy and tolerability of anti-TNF agents in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who had failed first-line non-steroidal anti-inflammatory (NSAID) treatment. Efficacy data from RCTs were used to calculate the number needed to treat (NNT) for individual anti-TNFs and then the cost per responder was determined to provide an indication of the value of each therapy...
July 4, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27366922/certolizumab-pegol-for-treating-axial-spondyloarthritis
#14
Julianna Desmarais, Secia Beier, Atul Deodhar
INTRODUCTION: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the spine and sacroiliac (SI) joints. The spectrum of axSpA includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Evidence has supported the use of TNF alpha inhibitors (TNFi) in treating these diseases, with good efficacy and tolerable safety profiles. Certolizumab pegol (CZP) is an anti-TNF alpha (TNFa) agent with data to support its use in both AS and nr-axSpA. AREAS COVERED: The pharmacologic properties of CZP were reviewed...
August 2016: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27309497/is-there-any-gender-specific-difference-in-the-cut-off-values-of-ankylosing-spondylitis-disease-activity-score-in-patients-with-axial-spondyloarthritis
#15
Gamze Kilic, Erkan Kilic, Salih Ozgocmen
AIM: To assess the validity of Assessment in Spondyloarthritis International Society (ASAS) endorsed Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (-CRP) and ASDAS erythrocyte sedimentation rate (-ESR) in axial spondyloarthritis (axSpA) and to estimate the cut-off values for male and female patients with axSpA. METHODS: Patients with axSpA were assessed for disease activity, functions, mobility and AS Quality of Life (ASQoL) and pain. The discriminant ability of ASDAS versions was assessed using standardized mean differences...
June 16, 2016: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/27200883/sustained-improvements-in-workplace-and-household-productivity-and-social-participation-with-certolizumab-pegol-over-96-weeks-in-patients-with-axial-spondyloarthritis-including-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis
#16
der Heijde D van, J Braun, M Rudwaleit, O Purcaru, A Kavanaugh
No abstract text is available yet for this article.
November 2014: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27200870/long-term-maintenance-of-improvements-in-patient-reported-outcomes-with-certolizumab-pegol-in-patients-with-axial-spondyloarthritis-including-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-96-week-results-of-the-rapid-axspa-study
#17
J Sieper, A Kivitz, A van Tubergen, A Deodhar, B Szegvari, T Nurminen, R Landewé
No abstract text is available yet for this article.
November 2014: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27188328/axial-spondyloarthritis
#18
Joachim Sieper, Jürgen Braun, Maxime Dougados, Dominique Baeten
The term axial spondyloarthritis covers both non-radiographic disease and radiographic disease (also known as ankylosing spondylitis). Some studies have been performed to investigate the prevalence of axial spondyloarthritis, although most are limited to patients with radiographic disease. A strong genetic association has been shown between axial spondyloarthritis and human leukocyte antigen-B27 (HLA-B27), but the pathogenetic role of HLA-B27 has not yet been clarified. Tumour necrosis factor (TNF), IL-17, IL-23 and downstream pathways also seem to be important - based on the good results of therapies directed against these molecules - but their exact role in the inflammatory process is also not yet clear...
2015: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/27125522/high-disease-activity-according-to-the-ankylosing-spondylitis-disease-activity-score-is-associated-with-accelerated-radiographic-spinal-progression-in-patients-with-early-axial-spondyloarthritis-results-from-the-german-spondyloarthritis-inception-cohort
#19
Denis Poddubnyy, Mikhail Protopopov, Hildrun Haibel, Jürgen Braun, Martin Rudwaleit, Joachim Sieper
OBJECTIVE: The aim of this work was to investigate the association between disease activity measured by the Ankylosing Spondylitis Disease Activity Score (ASDAS) and radiographic spinal progression in patients with early axial spondyloarthritis (axSpA). METHODS: Altogether, 178 patients with definite axSpA (100 with ankylosing spondylitis and 78 with non-radiographic axSpA) were included. Spinal radiographs (baseline and year 2) were assessed according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and for the presence of syndesmophytes...
April 28, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27094940/asas-classification-criteria-for-axial-spondyloarthritis-time-to-modify
#20
REVIEW
Nurullah Akkoc, Muhammad A Khan
The relationship between ankylosing spondylitis and the recently proposed entity called axial spondyloarthritis with its radiographic and non-radiographic forms that have been defined by the Assessment of Spondyloarthritis International Society (ASAS) criteria for axial spondyloarthritis (axSpA), is currently being debated. The Food and Drug Agency (FDA) had criticized the ASAS criteria and the studies which used these criteria to enroll patients in a clinical trial of certolizumab and adalimumab for the treatment of non-radiographic axial spondyloarthritis...
June 2016: Clinical Rheumatology
keyword
keyword
111757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"